Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.

about

Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)5-Azacytidine for the treatment of myelodysplastic syndromes.

P2860

Q36522939-39C7B1FE-21F0-459E-B41D-75F1458BEF6A Q38102062-ABE6F679-9E43-4ED2-92B4-6538844857A4

P2860

Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.

Item

http://www.wikidata.org/entity/Q38470137

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Pilot study on combination of ...... tory anemia with excess blast.

@en

type

Item

label

Pilot study on combination of ...... tory anemia with excess blast.

@en

prefLabel

Pilot study on combination of ...... tory anemia with excess blast.

@en

P1476

Pilot study on combination of ...... tory anemia with excess blast.

@en

P2093

Byung Woog Kang

http://www.w3.org/2001/XMLSchema#string

Jang Soo Suh

http://www.w3.org/2001/XMLSchema#string

Jong Gwang Kim

http://www.w3.org/2001/XMLSchema#string

Joon Ho Moon

http://www.w3.org/2001/XMLSchema#string

Sang Kyun Sohn

http://www.w3.org/2001/XMLSchema#string

Soo Jung Lee

http://www.w3.org/2001/XMLSchema#string

Yee Soo Chae

http://www.w3.org/2001/XMLSchema#string

Yoo Jin Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.

Targeting DNA methylation for epigenetic therapy.

Nucleoside analogues in the treatment of haematological malignancies.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Mechanisms of apoptosis induction by nucleoside analogs.

P304

367-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-011-1321-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21947085

http://www.w3.org/2001/XMLSchema#string

Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.

about

P2860

P2860

Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698